课题基金 / 基金详情

CELLULAR INVASION BY GROUP B STREPTOCOCCI

CELLULAR INVASION BY GROUP B STREPTOCOCCI
B 族链球菌的细胞入侵
批准号:
3145154
负责人:
CRAIG E. RUBENS
金额:
$13.9万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
1990
资助国家:
美国
项目状态:
已结题
起止时间:
1990-07-01 至 1993-06-30

项目摘要

项目成果

CRAIG E. RUBENS的其他基金

相似基金

相关文献

中文摘要
翻译
B群链球菌(GBS)是细菌性败血症的最常见原因
英文摘要
Group B streptococci (GBS) are the most common cause of bacterial sepsis and meningitis in the newborn infant. Although an extensive literature exists describing the immunology and epidemiology of GBS infection in neonates, very little information exists on the specific mechanisms this organism uses to induce disease. We have developed an in utero model of neonatal sepsis, induced by GBS, in subhuman primates - M. nemestrina or pigtail macaques. These infants display all of the stigmata of human infants infected by GBS in utero. Lung ultrastructural studies of infant primates with GBS pneumonia have shown that GBS are capable of invading alveolar epithelial cells. Based on this data, we have developed in vitro assays of epithelial cell invasion by GBS. This proposal seeks to define the characteristics of entry by GBS into epithelial cells. The investigation will first characterize the bacterial and cellular factors required by GBS for invasion of primarily respiratory epithelial cell lines. Secondly, we will investigate the ability of GBS to enter and traverse (trancytosis) from the apical to the basoloateral surface of a polar monolayer of epithelial cells. These experiments should provide insight into the mechanisms GBS use to penetrate and traverse across eukaryotic cells. We propose to identify the putative virulence factors produced by GBS that are responsible for the invasion phenotype. Transposon mutants in production of capsule and hemolysin have been made previously and will be screened for their ability to invade epithelial cells. Transposon mutagenesis will be used to derive new isogenic mutant strains of B|GBS which are unable to enter epithelial cells in vitro. The virulence of invasion mutants will be tested for their ability to induce GBS infections, first in a neonatal rat sepsis model, and subsequently, specific invasion mutants will be tested in utero in the GBS neonatal primate sepsis model. Those mutants incapable of invasion and subsequently shown to be avirulent in animal models will be further characterized using molecular biologic techniques. The genes important for invasion determinants, identified by transposon mutagenesis, will be cloned and the gene products identified using standardized gene expression assays. These studies should begin to identify using standardized gene expression assays. These studies should begin to identify the bacterial traits important in the early steps in the pathogenesis of neonatal infections caused by Group B streptococci.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
NEW MODEL OF ASCENDING INFECTION-RELATED PREMATURE BIRTH
  • 批准号:
    8172769
  • 项目类别:
  • 资助金额:
    $15.51万
  • 财政年份:
    2010
  • 负责人:
    CRAIG E. RUBENS
  • 依托单位:
NEW MODEL OF ASCENDING INFECTION-RELATED PREMATURE BIRTH
  • 批准号:
    7958877
  • 项目类别:
  • 资助金额:
    $15.76万
  • 财政年份:
    2009
  • 负责人:
    CRAIG E. RUBENS
  • 依托单位:
EXPERIMENTAL MODEL FOR CHORIOAMNIONITIS AND PRETERM LABOR
  • 批准号:
    7716383
  • 项目类别:
  • 资助金额:
    $15.78万
  • 财政年份:
    2008
  • 负责人:
    CRAIG E. RUBENS
  • 依托单位:
Role of a novel signal transduction pathway in GBS
  • 批准号:
    6805782
  • 项目类别:
  • 资助金额:
    $30.53万
  • 财政年份:
    2003
  • 负责人:
    CRAIG E. RUBENS
  • 依托单位:
国内基金
海外基金
基于多组学技术研究肠道微生物在猕猴(Macaca mulatta)衰老过程中的作用机制
  • 批准号:
    32370450
  • 项目类别:
    面上项目
  • 资助金额:
    50万元
  • 批准年份:
    2023
  • 负责人:
    范振鑫
  • 依托单位:
藏酋猴(Macaca thibetana)体内种子传播过程中微生物菌群复合体时空动态及其作用机制研究
  • 批准号:
    32370521
  • 项目类别:
    面上项目
  • 资助金额:
    50万元
  • 批准年份:
    2023
  • 负责人:
    潘慧娟
  • 依托单位:
太行山猕猴(Macaca mulatta tcheliensis)雌性的配偶选择
  • 批准号:
    32070446
  • 项目类别:
    面上项目
  • 资助金额:
    58.0万元
  • 批准年份:
    2020
  • 负责人:
    路纪琪
  • 依托单位:
猕猴(Macaca mulatta)衰老过程中凝血功能变化规律及基因表达调控机制研究
  • 批准号:
    --
  • 项目类别:
    --
  • 资助金额:
    58万元
  • 批准年份:
    2020
  • 负责人:
    范振鑫
  • 依托单位: